Condition: Pulmonary Tuberculosis · Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drugs, can shorten treatment duration to 4 months and be as effective and safer than current WHO endorsed treatment regimen given for 6-months. The study will compare different drug combinations in two groups of patients: those whose TB is sensitive to fluoroquinolones and those whose TB is resistant to fluoroquinolones. Participants will be randomly assigned to receive either the new treatment or the standard treatment. The study will last for 16 months for each participant and will measure how well the treatments work and how safe they are.
This description comes directly from the study's public registry record.
Otsuka Call Center · +1 844-687-8522 · Otsuka-ProfessionalServices@otsuka-us.com
Always discuss trial participation with your own doctor first.
| Capital Medical University - Beijing Chest Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province | Fuzhou, Fujian, China | Not Yet Recruiting |
| The Third People's Hospital of Shenzhen | Shenzhen, Guangdong, China | Not Yet Recruiting |
| Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital) | Wuhan, Hubei, China | Not Yet Recruiting |
| The Second Hospital of Nanjing | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Shandong Public Health Clinical Center | Jinan, Shandong, China | Not Yet Recruiting |
| Huashan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanghai Pulmonary Hospital - Pneumology | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Public Health Clinical Center of Chengdu | Chengdu, Sichuan, China | Not Yet Recruiting |
| National Center for Tuberculosis and Lung Disease | Tbilisi, Georgia | Recruiting |
| Japan Anti-Tuberculosis Association Fukujuji Hospital | Kiyose, Tokyo, Japan | Not Yet Recruiting |
| IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology | Chisinau, Chisinau City, Moldova | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07209761